About imiglucerase
Imiglucerase manufacturers include the originator Sanofi (Cerezyme, developed by Genzyme) and biosimilar producers such as ISU Abxis in Korea. Imiglucerase is a recombinant form of the enzyme glucocerebrosidase. It is used as long-term enzyme replacement therapy for Gaucher disease, an inherited disorder in which a fatty substance builds up in the spleen, liver and bones. Pharmaceutical companies can source imiglucerase through supply, biosimilar licensing or technology transfer.
Imiglucerase key facts
|
Property |
Imiglucerase |
|---|---|
|
INN |
Imiglucerase |
|
Molecule type |
Recombinant human glucocerebrosidase (acid beta-glucosidase), made in CHO cells, with mannose-terminated glycans |
|
ATC code |
A16AB02 |
|
Drug class |
Enzyme replacement therapy |
|
Brand name |
Cerezyme |
|
Originator |
Genzyme, now Sanofi |
|
Biosimilar |
Abcertin (ISU Abxis, Korea) |
|
Dosage form and strength |
Powder for concentrate for solution for infusion, 400 U vial |
|
Dose |
Individualised; typically 2.5–60 U/kg every 2 weeks by intravenous infusion |
|
Indications |
Gaucher disease type 1 (and non-neurological symptoms of type 3 in the EU) |
|
First approval |
US FDA, 1994 (replacing placenta-derived alglucerase) |
|
Competing therapies |
Velaglucerase alfa (VPRIV); taliglucerase alfa (Elelyso); oral eliglustat and miglustat |
|
Biosimilar status |
Approved in Korea and some other markets; none in the US or EU |
Imiglucerase manufacturers and licensing history
Genzyme first developed alglucerase (Ceredase), extracted from human placentas, and replaced it with recombinant imiglucerase (Cerezyme), approved by the FDA in 1994. Cerezyme became the standard treatment for Gaucher disease. Sanofi acquired Genzyme in 2011.
In 2009, a virus contamination at Genzyme's Allston plant caused a global Cerezyme shortage, which sped up approval of competitors such as Takeda's velaglucerase alfa and Pfizer/Protalix's taliglucerase alfa. Oral substrate reduction therapies, eliglustat and miglustat, are also available.
ISU Abxis developed Abcertin, an imiglucerase biosimilar approved in Korea. Buyers should confirm glycan profile, enzyme activity, comparability data, GMP status and cold-chain capability before choosing a partner.
Imiglucerase dosage forms and dossier types
Imiglucerase is supplied as lyophilised powder in 400 U vials, reconstituted and diluted for intravenous infusion.
|
Form |
Strengths |
Typical dossier |
Notes |
|---|---|---|---|
|
Imiglucerase powder for infusion |
400 U vial |
US BLA; EU MAA; national biosimilar |
Reference Cerezyme |
|
Imiglucerase drug substance |
Bulk |
Biologics master file |
Mannose-terminated glycans required for uptake |
|
Target market |
Dossier format |
Key requirement |
|---|---|---|
|
United States |
BLA / 351(k) |
No biosimilar approved |
|
European Union |
Biosimilar MAA |
Comparability to Cerezyme |
|
Korea, other markets |
National biosimilar pathway |
Abcertin approved in Korea |
Imiglucerase regulatory and patent status
Imiglucerase was approved in the US in 1994 and is long off-patent. Biosimilars are approved in Korea and some other markets, but not in the US or EU. Gaucher disease is rare, so products hold orphan designations and are often supplied through specialist programmes.
Imiglucerase mechanism of action and therapeutic use
In Gaucher disease, lack of glucocerebrosidase causes glucocerebroside to build up in macrophages, enlarging the spleen and liver and damaging bones and blood counts. Imiglucerase replaces the missing enzyme. Its mannose-terminated sugars target it to macrophages through mannose receptors. It is given by infusion every 2 weeks, usually for life.
Imiglucerase licensing and sourcing
Imiglucerase suppliers and licensing partners typically offer finished-product supply, biosimilar licensing or technology transfer. Buyers usually compare GMP status, comparability data, cold-chain capability and territory availability. Current offers and supplier contacts are listed among the imiglucerase manufacturers on Pipelinepharma.
Frequently asked questions about imiglucerase
Who manufactures imiglucerase? Sanofi makes Cerezyme, developed by Genzyme. ISU Abxis makes the biosimilar Abcertin in Korea.
What is imiglucerase used for? Imiglucerase is used as enzyme replacement therapy for Gaucher disease type 1, and for non-neurological symptoms of type 3 in the EU.
What forms and strengths of imiglucerase are available? Imiglucerase is available as a 400 U lyophilised powder for intravenous infusion.
Is there a biosimilar of imiglucerase? Yes, in Korea (Abcertin) and some other markets. None is approved in the US or EU.
What other treatments exist for Gaucher disease? Other enzyme therapies include velaglucerase alfa and taliglucerase alfa. Oral options include eliglustat and miglustat.
Popular Searches
Want unlimited access to the Pipelinepharma database?
Become a subscriber to unlock:
-
Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.
-
Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.
-
Higher profitability: compare multiple supplier offers and secure the best commercial terms.
-
Expanded network: view supplier portfolios and stay updated on new products.
-
Value-added product ideas: discover products with lower competition potential.
-
Access to marketing authorizations for sale: find already registered products in your target markets.